Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEEM-2: BCX9930 Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
jRCT2051210180Active, not recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Nov 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing BCX9930 with Placebo (2 arms). Primary endpoint: Change from baseline in hemoglobin at Week 12. Started Nov 2021; status: active, not recruiting.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2051210180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210180.